ASC30_39 FDC / Ascletis - LARVOL DELTA

Ascletis Pharma Inc…announces that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30, once-daily oral small molecule GLP-1R agonist and ASC39, once-daily oral small molecule amylin-selective amylin receptor agonist, for clinical development. (PRNewswire) - "Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets for the treatment of obesity in the third quarter of 2026...ASC30_39 FDC tablets, dosed orally in dogs, demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours...The combination of the excellent pharmacokinetic profile of ASC30_39 FDC, the potential best- in-class efficacy and gastrointestinal (GI) tolerability of ASC30 and the first eloralintide-like small molecule amylin support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for the treatment of obesity."

IND • Preclinical • Obesity